Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients

Human primary glioblastomas (GBM) often harbor mutations within the epidermal growth factor receptor (EGFR). Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively induce cell death in these models. However, EGFR inhibitors have shown little ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Shayna, Zhao, Rui, Haeno, Hiroshi, Vivanco, Igor, Michor, Franziska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766249/
https://www.ncbi.nlm.nih.gov/pubmed/29293494
http://dx.doi.org/10.1371/journal.pcbi.1005924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766249/
https://www.ncbi.nlm.nih.gov/pubmed/29293494
http://dx.doi.org/10.1371/journal.pcbi.1005924

Ejemplares similares